Search research articles
Contact Us
Filters
Showing results (331-340 of 418) with videos related to
Page
of 42
Sort By:
JCO Precision Oncology
|
April 11, 2024
Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2
Jun Gong, Alain C Mita, Zihan Wei, et al.
JCO Precision Oncology
|
April 9, 2024
Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E
Monica F Chen, Zihe Song, Helena A Yu, et al.
The New England Journal of Medicine
|
June 6, 2019
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
Caroline Robert, Jean J Grob, Daniil Stroyakovskiy, et al.
JCO Precision Oncology
|
August 8, 2022
Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B
Philippe L Bedard, Shuli Li, Kari B Wisinski, et al.
JCO Precision Oncology
|
December 18, 2024
Phase II Study of Defactinib (VS6063) in Patients With Tumors With <i>NF2</i> Loss: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol U
Marjorie G Zauderer, Opeyemi Jegede, David M Jackman, et al.
JCO Precision Oncology
|
April 11, 2024
Phase II Study of Erdafitinib in Patients With Tumors With <i>FGFR</i> Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1
Jun Gong, Alain C Mita, Zihan Wei, et al.
Biorxiv : the Preprint Server for Biology
|
May 18, 2026
Weak supervision of H&E slides reveals systems-level biology and functional states that govern therapeutic resistance
Tiago Goncalves, Dagoberto Pulido, Carmen M Perrino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 27, 2016
Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib
Georgina V Long, Jeffrey S Weber, Jeffrey R Infante, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 13, 2020
Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)
Keith T Flaherty, Robert J Gray, Alice P Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 5, 2022
Antitumor Activity of a Mitochondrial-Targeted HSP90 Inhibitor in Gliomas
Shiyou Wei, Delong Yin, Shengnan Yu, et al.
Page
of 42
Search research articles
Search
Showing results (331-340 of 418) with videos related to
Sort By:
Page
of 42
JCO Precision Oncology
|
April 11, 2024
Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2
Jun Gong, Alain C Mita, Zihan Wei, et al.
JCO Precision Oncology
|
April 9, 2024
Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E
Monica F Chen, Zihe Song, Helena A Yu, et al.
The New England Journal of Medicine
|
June 6, 2019
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
Caroline Robert, Jean J Grob, Daniil Stroyakovskiy, et al.
JCO Precision Oncology
|
August 8, 2022
Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B
Philippe L Bedard, Shuli Li, Kari B Wisinski, et al.
JCO Precision Oncology
|
December 18, 2024
Phase II Study of Defactinib (VS6063) in Patients With Tumors With <i>NF2</i> Loss: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol U
Marjorie G Zauderer, Opeyemi Jegede, David M Jackman, et al.
JCO Precision Oncology
|
April 11, 2024
Phase II Study of Erdafitinib in Patients With Tumors With <i>FGFR</i> Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1
Jun Gong, Alain C Mita, Zihan Wei, et al.
Biorxiv : the Preprint Server for Biology
|
May 18, 2026
Weak supervision of H&E slides reveals systems-level biology and functional states that govern therapeutic resistance
Tiago Goncalves, Dagoberto Pulido, Carmen M Perrino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 27, 2016
Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib
Georgina V Long, Jeffrey S Weber, Jeffrey R Infante, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 13, 2020
Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)
Keith T Flaherty, Robert J Gray, Alice P Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 5, 2022
Antitumor Activity of a Mitochondrial-Targeted HSP90 Inhibitor in Gliomas
Shiyou Wei, Delong Yin, Shengnan Yu, et al.
Page
of 42